What You Should Know
- PGxAI, an AI-native precision medicine company specializing in personalized prescribing and human drug-metabolism intelligence, announced that its Andromeda clinical decision-support platform is now a Qualified Solution on Mayo Clinic Platform.
- The qualification via Mayo Clinic Platform’s Solutions Studio provides PGxAI with a structured framework for provider-led evaluation, algorithmic validation, clinical workflow integration, and deployment readiness across health systems.
- Andromeda unifies pharmacogenomics (PGx), multi-omics datasets, phenoconversion-related factors, drug-drug and drug-condition interactions, real-world evidence (RWE), and clinical context into an auditable, clinician-reviewable decision layer embedded directly into electronic health record (EHR) prescribing workflows.
- The platform addresses trial-and-error medicine by optimizing initial therapy selection, precise metabolic dosing, and adverse drug event (ADE) mitigation across health systems, payers, clinical laboratories, and biopharmaceutical sponsors.
- PGxAI was co-founded by Dr. Mike Zack, M.D., Ph.D., MPH (a top 1% cited precision medicine scientist) and Allan Gobbs (life sciences entrepreneur with nine exits, including five IPOs).
Multi-Omics Ingestion, Phenoconversion Accounting, and Mayo Clinic Validation
Andromeda translates high-dimensional biological and pharmacological data into in-workflow decision support:
- Unified Multi-Omics and Phenoconversion Engine: Integrates patient-specific pharmacogenomics, transcriptomic/metabolomic markers, and real-time clinical variables (such as concurrent medications, liver/kidney function, and inflammatory markers) to account dynamically for drug-drug interactions and enzymatic phenoconversion.
- Clinician-Reviewable Transparency: Employs an explainable AI architecture with auditable data lineage and verifiable medical citations, ensuring the final prescribing authority and clinical judgment remain firmly with the physician.
- Seamless In-Workflow Prescribing Integration: Designed to embed natively within major EHR prescribing and computerized physician order entry (CPOE) systems, surfacing actionable dosage adjustments and safer alternative molecules before an order is signed.
- Mayo Clinic Platform Qualification: Evaluated through the Solutions Studio program for clinical relevance, algorithmic efficacy, data security, and operational readiness, opening structured pathways for provider-led pilots across major health systems.
- Enterprise-Scale Life Sciences Utility: Extends precision pharmacology intelligence to biopharma partners to improve clinical trial cohort stratification, predict therapeutic response rates, and de-risk drug development strategies.
“Our goal is to make the right medication and dose the starting point of treatment, rather than the result of months of trial and error,” said Dr. Mike Zack, M.D., Ph.D., MPH, CEO and Co-Founder of PGxAI. “Andromeda makes personalized prescribing practical in everyday clinical care, with transparent reasoning, verifiable sources and the final decision remaining with the clinician.”
